Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A new biologic could shake up EoE treatment. The phase 3 CROSSING trial found that tezepelumab (Tezspire) significantly improved swallowing difficulty and helped more patients achieve histologic remission compared to placebo — with benefits sustained through week 52. AstraZeneca and Amgen plan to share the data with regulatory authorities, signaling a potential new treatment option for a condition where nearly half of patients fall short with current therapies.
A new biologic could shake up EoE treatment. The phase 3 CROSSING trial found that tezepelumab (Tezspire; AstraZeneca/Amgen) significantly improved both the frequency and severity of dysphagia (difficulty swallowing) and histologic remission rates in adolescents and adults with eosinophilic esophagitis (EoE) compared to placebo — with results holding strong through week 52. The drug, already FDA-approved for severe asthma and chronic rhinosinusitis with nasal polyps, is now being positioned as a potential second biologic option for EoE.
The trial enrolled 368 patients aged 12–80 with symptomatic, histologically active EoE on maintenance therapy. Participants received subcutaneous tezepelumab (low or high dose) every 4 weeks. Histologic remission was defined as a peak esophageal eosinophil count of ≤6 per high-power field. The safety profile was consistent with its approved indications.
Key Takeaways:
Why it matters: EoE is a chronic, immune-mediated condition that can severely impact quality of life. A new biologic with a first-in-class mechanism and a convenient monthly dosing schedule could meaningfully expand the treatment toolkit for clinicians and patients alike.
